Corvus Pharmaceuticals (CRVS) Profit After Tax (2015 - 2026)

Corvus Pharmaceuticals' Profit After Tax history runs 12 years deep, the most recent figure standing at -$13.9 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 191.43% year-over-year to -$13.9 million; the TTM figure through Mar 2026 stood at -$16.8 million (up 50.93% YoY), while the FY2025 annual figure was -$102.1 million, down 12.78% from the prior year.
• Profit After Tax for Q1 2026 stood at -$13.9 million, down from -$10.2 million in the prior quarter.
• The five-year high for Profit After Tax was $15.2 million in Q1 2025, with the low at -$39.6 million in Q3 2024.
• The 5-year median for Profit After Tax is -$7.9 million (2023), against an average of -$8.7 million.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax plunged 560.0% in 2024, then jumped 367.09% in 2025.
• Corvus Pharmaceuticals' Profit After Tax stood at -$6.8 million in 2022, then increased by 14.95% to -$5.7 million in 2023, then sank by 589.42% to -$39.6 million in 2024, then surged by 74.35% to -$10.2 million in 2025, then slumped by 37.07% to -$13.9 million in 2026.
• Business Quant data shows CRVS's Profit After Tax at -$13.9 million in Q1 2026, -$10.2 million in Q3 2025, and -$8.0 million in Q2 2025.